Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.




Feds to Review March-In Authority on Drug Patents

Pending FDA approval, agreement expected to support once-daily stimulant medication. 




Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.



Manufacturer to withdraw preterm birth drug, amid latest FDA push. 




Latest investigation signals more scrutiny of pharmacy benefit managers and their role in treatment cost and coverage. 







The platform is designed to reduce barriers to care for patients with COVID-19.

In its ninth year, the survey includes the opinions of over 240 US-based patient groups on the performance of the pharmaceutical industry in 2021.

The HBA announced the 2023 Woman of the Year, Honorable Mentor, and STAR recipients.

The report highlights various treatments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma, and breast cancer.

The FDA tapped the Reagan-Udall Foundation to launch the initiative.